William Blair lowered their Q3 2025 EPS estimates for ResMed in a research report issued on Monday, February 3rd. William Blair analyst M. Andrew now anticipates that the medical equipment provider ...

Shares of ResMed Inc. RMD shed 2.23% to $237.18 Thursday, on what proved to be an all-around mixed trading session for the ...

ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...

ResMed (NYSE:RMD) received an updated price target from RBC Capital Markets following the disclosure of its second-quarter ...

ResMed’s (ASX:RMD) half-year FY25 results reflect a company that is not only thriving in its core business but is also ...

Needham analyst Michael Matson has maintained their neutral stance on RMD stock, giving a Hold rating on January 29.Invest with Confidence: ...

ResMed Inc. (NYSE:RMD – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the fifteen ratings firms that are covering the firm, Marketbeat.com reports. One research ...

In a report released today, Brett Fishbin from KeyBanc maintained a Buy rating on Resmed (RMD – Research Report), with a price target of ...

Significant growth in digital health and sleep care solutions fueled the company's performance. ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and ...

In future, our dividend and earnings forecasts will be shown on a USD per share basis. Each ResMed share is equivalent to 10 CDIs. The shares are traded in the US, whereas the CDIs are traded on ...

ResMed’s competitors might be hamstrung by potential tariffs imposed by the US, boss Mick Farrell says, but adds the company, ...

ResMed (NYSE:RMD), a leader in sleep apnea and respiratory care solutions, reported strong fiscal 2025 second-quarter earnings on Thursday, Jan. 30. The medical device company outperformed analyst ...